Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of “Moderate Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $361.5556.

A number of research firms have commented on KRYS. Citigroup increased their price objective on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. TD Cowen upped their price objective on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. HC Wainwright boosted their price target on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. Finally, Bank of America lifted their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th.

Insider Activity at Krystal Biotech

In other news, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares of the company’s stock, valued at approximately $347,270. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock valued at $8,243,923 over the last ninety days. Corporate insiders own 13.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its stake in shares of Krystal Biotech by 469.9% in the fourth quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock worth $4,662,000 after purchasing an additional 15,591 shares in the last quarter. Handelsbanken Fonder AB increased its stake in shares of Krystal Biotech by 58.4% during the fourth quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock valued at $26,084,000 after acquiring an additional 39,000 shares during the period. Fisher Asset Management LLC bought a new position in Krystal Biotech during the 4th quarter valued at $933,000. Biondo Investment Advisors LLC raised its stake in shares of Krystal Biotech by 31.3% in the 4th quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock worth $16,797,000 after buying an additional 16,245 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Krystal Biotech by 15.6% during the fourth quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock worth $40,697,000 after acquiring an additional 22,231 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Up 0.3%

Shares of KRYS opened at $325.78 on Thursday. The firm has a market cap of $9.64 billion, a price-to-earnings ratio of 40.82 and a beta of 0.53. The business’s 50 day moving average is $340.79 and its two-hundred day moving average is $297.13. Krystal Biotech has a 52-week low of $132.31 and a 52-week high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, equities analysts expect that Krystal Biotech will post 7.27 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.